Table 4

Changes in glycemic control, quality of life and disease burden among persons who continued FSL-FGM for at least 2 years and persons who had stopped FSL-FGM before the 2-year follow-up period was completed

Baseline (A)1 year (B)2 years (C)C vs AC vs BOverall difference between groups
Continued FSL-FGMStopped FSL-FGMContinued FSL-FGMStopped FSL-FGMContinued FSL-FGMStopped FSL-FGMContinued FSL-FGMStopped FSL-FGMContinued FSL-FGMStopped
FSL-FGM
Glycemia
 HbA1c62.4 (60.8 to 64.0)59.0 (56.2 to 61.8)58.3 (56.8 to 59.7)56.4 (53.8 to 58.9)58.9 (57.2 to 60.6)56.7 (53.6 to 59.8)3.5 (−6.4 to −0.7)−2.4 (−7.5 to 2.7)0.6 (−2.1 to 3.4)0.3 (−4.6 to 5.2)2.2 (−1.3 to 5.8)
 n259821916226082
 Hypoglycemic events61.8 (52.8 to 70.8)67.5 (51.1 to 83.9)60.3 (49.7 to 70.9)72.3 (52.4 to 92.2)51.3 (43.0 to 59.7)50.7 (35.0 to 66.4)−10.5 (−25.4 to 4.5)−16.8 (−44.5 to 10.9)−9.0 (−25.5 to 7.5)−21.6 (−52.5 to 9.4)0.6 (−17.2 to 18.4)
 n250752426922965
 Quality of life
 EQ-VAS70.9 (69.5 to 74.2)67.7 (63.6 to 71.9)73.8 (71.2 to 76.4)69.6 (64.9 to 74.2)74.8 (71.9 to 77.6)74.8 (71.9 to 77.6)2.9 (−1.7 to 7.4)5.3 (−2.8 to 13.4)0.9 (−3.8 to 5.7)3.5 (−5.0 to 12.0)1.7 (−4.2 to 7.6)
 n260822608226580
 EQ-5D-3L Dutch tariff0.85 (0.83 to 0.87)0.84 (0.80 to 0.88)0.87 (0.85 to 0.90)0.84 (0.80 to 0.88)0.88 (0.85 to 0.90)0.81 (0.77 to 0.85)0.02 (−0.02 to 0.06)−0.03 (−0.10 to 0.04)0.002 (−0.04 to 0.04)−0.03 (−0.1 to 0.04)0.07 (0.02 to 0.1)
 n260822608225680
 SF-12v2 PCS score37.6 (36.9 to 38.3)38.7 (37.5 to 40.0)47.4 (46.4 to 48.4)47.1 (45.3 to 48.8)47.2 (46.2 to 48.2)46.5 (44.8 to 48.3)9.6 (8.1 to 11.0)7.8 (5.2 to 11.5)−0.2 (−1.9 to 1.5)−0.5 (−3.5 to 2.5)0.7 (−1.4 to 2.7)
 n260822608226082
 SF-12v2 MCS score50.1 (48.8 to 51.3)47.6 (45.4 to 49.9)51.1 (50.0 to 52.1)47.8 (45.9 to 49.6)50.0 (48.9 to 51.1)45.0 (43.1 to 47.0)−0.03 (−2.1 to 2.0)−2.6 (−6.2 to 1.1)−1.1 (−2.9 to 0.8)−2.7 (−6.1 to 0.6)5.0 (2.7 to 7.3)
 n260822547925479
 Disease burden
 Hospital admissions0.1 (0.07 to 0.2)0.1 (−0.04 to 0.2)0.1 (0.03 to 0.2)0.02 (−1.0 to 0.1)2.1 (−1.4 to 5.5)0.6 (−5.5 to 6.7)1.9 (−2.3 to 6.1)0.5 (−7.0 to 8.0)2.0 (−2.2 to 6.2)0.6 (−6.9 to 8.1)2.1 (−1.4 to 5.5)
 n260822608225982
 Lost working days4.9 (1.6 to 8.1)7.2 (1.4 to 13.0)2.2 (−0.7 to 5.0)8.0 (3.0 to 13.1)3.4 (−0.7 to 7.5)8.0 (3.0 to 13.1)−1.5 (−7.9 to 4.9)0.9 (−10.5 to 12.2)1.2 (−4.9 to 7.3)0.01 (−10.8 to 10.8)−4.6 (−13.0 to 3.7)
 n260822608225782
  • Data are presented as mean (difference) with 95% CI.

  • HbA1c concentrations are presented in mmol/mol.

  • EQ-5D-3L, three-level version of EuroQol 5-Dimension; EQ-VAS, EQ-Visual Analogue Scale; FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12v2, 12-Item Short Form Health Survey version 2.